美國(guó)OncoMed www.oncomed.com 
OncoMed制藥是一個(gè)臨床階段的公司發(fā)現(xiàn)并開(kāi)發(fā)新型療法，針對(duì)癌癥干細(xì)胞，細(xì)胞認(rèn)為是能夠驅(qū)動(dòng)腫瘤生長(zhǎng)，復(fù)發(fā)和轉(zhuǎn)移。癌癥干細(xì)胞研究的領(lǐng)導(dǎo)者，該公司已建立了癌癥干細(xì)胞的蛋白質(zhì)抗體庫(kù)的實(shí)體腫瘤，如胰腺癌，乳腺癌，腸癌和肺癌的治療。 OncoMed已推進(jìn)到診所指，OMP-21M18-59R5，OMP的，和OMP-18R5，該目標(biāo)的關(guān)鍵癌癥干細(xì)胞的信號(hào)包括Notch和Wnt信號(hào)通路的三防癌干細(xì)胞的單克隆抗體。此外，OncoMed的管道包括了一些新的臨床前候選產(chǎn)品，針對(duì)多個(gè)驗(yàn)證癌癥干細(xì)胞的途徑。 OncoMed與拜耳醫(yī)藥保健制藥和葛蘭素史克公司已形成戰(zhàn)略聯(lián)盟。私人持有，OncoMed的投資者包括：The Vertical Group, Morgenthaler Ventures, Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures, Bay Partners and GlaxoSmithKline.

OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastasis. A leader in cancer stem cell research, the company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal and lung cancers. OncoMed has advanced three anti- cancer stem cell monoclonal antibodies into the clinic, OMP-21M18, OMP-59R5, and OMP-18R5, which target key cancer stem cell signaling pathways including Notch and Wnt. In addition, OncoMed's pipeline includes several novel preclinical product candidates targeting multiple validated cancer stem cell pathways. OncoMed has formed strategic alliances with Bayer HealthCare Pharmaceuticals and GlaxoSmithKline. Privately-held, OncoMed's investors include: US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures, Bay Partners and GlaxoSmithKline.